Regulatory News: Ipsen (Paris:IPN) today announced the appointment, of Gérard
Picot as Vice-President, Global Regulatory Affairs. He reports to Stéphane
Thiroloix, Executive Vice President, Corporate Development. This
appointment is within the context of the retirement of Mr William Jones. His main mission will be to enhance the regulatory position of Ipsen
its products and those of its partners worldwide, thanks to the strong
network of teams based in Paris (France), Slough (United Kingdom), and
Boston (United States). Gérard Picot brings
along a history of solid delivery in the regulatory arena, a rich
track-record of staff development, a strong strategic thinking ability
and a proven drive to partner through change. Gérard Picot, 55, holds a Doctorate in
Pharmaceutical Sciences and an MS in Drug Law from the University of
Paris. He started his career in 1982 within Merck, Sharpe & Dohme´s
US Regulatory Affairs Group. He then took in 1987 responsibility for
Drug Development at Laboratoires Fournier, before joining Bristol-Myers
Squibb´s Regulatory Affairs group in 1990
where he was most recently VP, Global Regulatory Sciences for Europe
Middle-East and Africa. Since 1991, Gérard
has been a member or permanent guest of EFPIA´s
(European Federation of Pharmaceutical Industry Associations)
Scientific, Technical and Regulatory Policy Committee. About Ipsen Ipsen is an innovation-driven international specialty pharmaceutical
group with over 20 products on the market and a total worldwide staff of
nearly 4,000. Its development strategy is based on a combination of
specialty products, which are growth drivers, in targeted therapeutic
areas (oncology, endocrinology and neuromuscular disorders), and primary
care products which contribute significantly to its research financing.
The location of its four Research & Development centres (Paris, Boston
Barcelona, London) and its peptide and protein engineering platform give
the Group a competitive edge in gaining access to leading university
research teams and highly qualified personnel. More than 700 people in
R&D are dedicated to the discovery and development of innovative drugs
for patient care.This strategy is also supported by an active policy of
partnerships. In 2007, Research and Development expenditure was about ?185
million, in excess of 20% of consolidated sales, which amounted to ?920.5
million while total revenues amounted to ?993.8
million. Ipsen´s shares are traded on Segment
A of Eurolist by EuronextTM (stock code: IPN
ISIN code: FR0010259150). Ipsen´s shares are
eligible to the "Service de Règlement
Différé" ("SRD") and the
Group is part of the SBF 120 index. For more information on Ipsen, visit
our website at www.ipsen.com. Ipsen Forward-looking statements The forward-looking statements and targets contained herein are based on
Ipsen´s management´s current views and assumptions. Such statements
involve known and unknown risks and uncertainties that may cause actual
results, performance or events to differ materially from those
anticipated herein. The targets contained herein were prepared without
taking into account external growth assumptions, which may alter the
parameters. These targets are based on data and assumptions regarded as
reasonable by the Group and depend on conditions or facts likely to
happen in the future, and not exclusively on historical data. Actual
results may depart significantly from the targets given the occurrence
of certain risks and uncertainties. The Group does not commit nor gives
any guarantee that it will meet the targets mentioned above. Moreover
the Research and Development process involves several stages at each of
which there is a substantial risk that the Group will fail to achieve
its objectives and be forced to abandon its efforts in respect of a
product in which it has invested significant sums. Therefore, the Group
cannot be certain that favourable results obtained during pre-clinical
trials will be confirmed subsequently during clinical trials, or that
the results of clinical trials will be sufficient to demonstrate the
safe and effective nature of the product concerned. Moreover, the
targets described in this document were prepared without taking into
account external growth assumptions, which may alter these parameters.
These targets are based on data and assumptions regarded as reasonable
by the Group. These targets depend on conditions or facts likely to
happen in the future, and not exclusively on historical data. Actual
results may depart significantly from these targets given the occurrence
of certain risks and uncertainties. The Group does not commit nor gives
any guarantee that it will meet the targets mentioned above. Ipsen
expressly disclaims any obligation or undertaking to update or revise
any forward looking statements, targets or estimates contained in this
press release to reflect any change in events, conditions, assumptions
or circumstances on which any such statements are based, unless so
required by applicable law. Ipsen´s business is subject to the risk
factors outlined in its information documents filed with the French Autorité des Marchés Financiers.
